Comparing special A2 dairy products with regular dairy in people with colorectal polyps
Tests special A2 milk, yogurt and cheese against regular dairy in adults after polyp removal.
Plain-language title generated from the registry record
Registry title: Effects of UNICLA-A2 Dairy Products on Patients at High-risk of Colorectal Cancer Development
Key facts
- Where
- Zaragoza, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 who have high-risk polyps in the colon or rectum and who regularly eat milk and dairy products.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- High-risk polyps found in screening or follow-up, for example at least 10 adenomas, at least 5 proximal serrated polyps, Serrated Polyposis Syndrome, early invasive colorectal cancer (stage pT1) removed by endoscopy, or a large flat or sessile lesion of at least 20 mm.
- Earlier treatment
- People must not need regular aspirin (ASA), NSAIDs, misoprostol, corticosteroids or statins during the study. People must not have had stomach, small intestine or colon surgery that affects how nutrients are absorbed.
Main reasons for not taking part
- Allergic reaction to compounds similar to the study products
- Incomplete or poor quality colonoscopy (Boston score below 6)
- Regular or expected need for aspirin (ASA), NSAIDs, misoprostol, corticosteroids or statins during the study
- Earlier stomach, small intestine or colon surgery that affects nutrient absorption
- History of familial adenomatous polyposis
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT04824053, who can take part
Where in Spain
- Angel Lanas ArbeloaZaragoza, SpainContact: Angel Lanas Arbeloa, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Instituto de Investigación Sanitaria Aragón
- Trial code
- NCT04824053
- Record updated
- 12 May 2026
- Original description
Dietary intervention with UNICLA-A2 milk products containing beta casein A2 protein, and higher levels of omega-3 fatty acids and selenium may contribute to maintain the intestinal integrity, reduce inflammatory processes, normalize the immune system, protect against oxidative damage and equilibrate the gut microbiota in high-risk colorectal cancer patients who have undergone polypectomyRead full original descriptionShow less
Comparative Analysis of the Effects of UNICLA-A2 Against Conventional Dairy Products Administered Daily in Patients at High-risk Colorectal Cancer Development Who Have Undergone Polypectomy
Dietary intervention with UNICLA-A2 milk products containing beta casein A2 protein, and higher levels of omega-3 fatty acids and selenium may contribute to maintain the intestinal integrity, reduce inflammatory processes, normalize the immune system, protect against oxidative damage and equilibrate the gut microbiota in high-risk colorectal cancer patients who have undergone polypectomy
Inclusion: Participants diagnosed with high-risk polyps in the colorectal cancer screening programme or in the relative's colon cancer prevention program or patients who are in follow-up due to prior detection of polyps with any of the following characteristics:; At least 10 adenomas; At least 5 proximal serrated polyps (PSP); At least 2 serrated polyps with diameters ≥10 mm; Serrated Polyposis Syndrome (SPS); Early invasive CRC (stage pT1) endoscopically resected (surgery not required); A sessile or flat lesion ≥ 20 mm with fragmented resection; Patients with previous resection of polyps in which the resection margin was not assessable and are considered susceptible to repeat colonoscopy; Patients with intramucosal carcinoma in situ or invasion of the lamina propria (pTis); Regular consumer of milk and dairy products; Informed consent form signed.
Exclusion: Concomitant acetylsalicylic acid (ASA), NSAIDs, misoprostol, corticosteroids or statins needed on a regular or predictable basis during the time of the study; Previous gastrointestinal surgery (colon or small intestine or gastric) that affects the absorption of nutrients; History of allergic reaction attributed to compounds of similar chemical composition to the study agents; History of familial adenomatous polyposis; Incomplete colonoscopy or with poor quality criteria, Boston <6.